Patents by Inventor Randy W. Scott

Randy W. Scott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Minimally invasive implantable neurostimulation system
    Patent number: 11957893
    Abstract: A neuromodulation therapy is delivered via at least one electrode implanted subcutaneously and superficially to a fascia layer superficial to a nerve of a patient. In one example, an implantable medical device is deployed along a superficial surface of a deep fascia tissue layer superficial to a nerve of a patient. Electrical stimulation energy is delivered to the nerve through the deep fascia tissue layer via implantable medical device electrodes.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: April 16, 2024
    Assignee: Medtronic, Inc.
    Inventors: Brad C. Tischendorf, John E. Kast, Thomas P. Miltich, Gordon O. Munns, Randy S. Roles, Craig L. Schmidt, Joseph J. Viavattine, Christian S. Nielsen, Prabhakar A. Tamirisa, Anthony M. Chasensky, Markus W. Reiterer, Chris J. Paidosh, Reginald D. Robinson, Bernard Q. Li, Erik R. Scott, Phillip C. Falkner, Xuan K. Wei, Eric H. Bonde, David A. Dinsmoor, Duane L. Bourget, Forrest C M Pape, Gabriela C. Molnar, Joel A. Anderson, Michael J. Ebert, Richard T. Stone, Shawn C. Kelley, Stephen J. Roddy, Timothy J. Denison, Todd V. Smith
  • Minimally invasive implantable neurostimulation system
    Patent number: 11957894
    Abstract: A neuromodulation therapy is delivered via at least one electrode implanted subcutaneously and superficially to a fascia layer superficial to a nerve of a patient. In one example, an implantable medical device is deployed along a superficial surface of a deep fascia tissue layer superficial to a nerve of a patient. Electrical stimulation energy is delivered to the nerve through the deep fascia tissue layer via implantable medical device electrodes.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: April 16, 2024
    Assignee: Medtronic, Inc.
    Inventors: Anthony M. Chasensky, Bernard Q. Li, Brad C. Tischendorf, Chris J. Paidosh, Christian S. Nielsen, Craig L. Schmidt, David A. Dinsmoor, Duane L. Bourget, Eric H. Bonde, Erik R. Scott, Forrest C M Pape, Gabriela C. Molnar, Gordon O. Munns, Joel A. Anderson, John E. Kast, Joseph J. Viavattine, Markus W. Reiterer, Michael J. Ebert, Phillip C. Falkner, Prabhakar A. Tamirisa, Randy S. Roles, Reginald D. Robinson, Richard T. Stone, Shawn C. Kelley, Stephen J. Roddy, Thomas P. Miltich, Timothy J. Denison, Todd V. Smith, Xuan K. Wei
  • Basophil granule proteins
    Patent number: 5747283
    Abstract: Several natural polypeptides (basophil granule proteins, "BGP") derived from the cytoplasmic granules of human basophils, and modified forms thereof, are described. These polypeptides, the DNA which encodes them and antibodies which recognize them, are useful as diagnostics for, and treatments for, pathologies involving inflammatory and IgE-mediated responses, parasitic and helminthic infections, hypersensitivity reactions and certain types of leukocytic leukemias.
    Type: Grant
    Filed: December 18, 1995
    Date of Patent: May 5, 1998
    Assignees: Incyte Pharnaceuticals, Inc., Mayo Foundation for Medical Education and Research
    Inventors: Randy W. Scott, Gerald J. Gleich, Craig G. Wilde
  • Recombinant purified protease nexin
    Patent number: 5495001
    Abstract: DNA segments encoding two slightly different protease nexin I forms (PN-I.alpha. and PN-I.beta.) are cloned and expressed to provide practical quantities of PN-I for diagnostic and therapeutic use. PN-I is a serine protease inhibitor useful in controlling conditions mediated by proteolytic activity.
    Type: Grant
    Filed: August 10, 1994
    Date of Patent: February 27, 1996
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Michael P. McGrogan, Randy W. Scott, Joffre B. Baker, Christian C. Simonsen, Sr.
  • Basophil granule proteins
    Patent number: 5476839
    Abstract: Several natural polypeptides (basophil granule proteins, "BGP") derived from the cytoplasmic granules of human basophils, and modified forms thereof, are described. These polypeptides, the DNA which encodes them and antibodies which recognize them, are useful as diagnostics for, and treatments for, pathologies involving inflammatory and IgE-mediated responses, parasitic and helminthic infections, hypersensitivity reactions and certain types of leukocytic leukemias.
    Type: Grant
    Filed: May 19, 1994
    Date of Patent: December 19, 1995
    Assignees: Incyte Pharmaceuticals, Inc., Mayo Foundation for Medical Education and Research
    Inventors: Randy W. Scott, Gerald J. Gleich, Craig G. Wilde
  • Basophil granule proteins
    Patent number: 5470825
    Abstract: Several natural polypeptides (basophil granule proteins, "BGP") derived from the cytoplasmic granules of human basophils, and modified forms thereof, are described. These polypeptides, the DNA which encodes them and antibodies which recognize them, are useful as diagnostics for, and treatments for, pathologies involving inflammatory and IgE-mediated responses, parasitic and helminthic infections, hypersensitivity reactions and certain types of leukocytic leukemias.
    Type: Grant
    Filed: June 15, 1994
    Date of Patent: November 28, 1995
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Randy W. Scott, Gerald J. Gleich, Craig G. Wilde
  • Protease nexin-I variants
    Patent number: 5457090
    Abstract: One or more amino acid residues within the reactive site region of protease nexin-I are altered in order to create analogs or variants of protease nexin-I. These analogs have substantially different protease specificities as well as different effects on regulating the activity of proteolytic enzymes which enzymes have substantial effects on a number of different physiological functions. Formulations containing the protease nexin-I variants and methods for administering these formulations to obtain desirable therapeutic results are disclosed.
    Type: Grant
    Filed: August 3, 1992
    Date of Patent: October 10, 1995
    Assignee: Incyte Pharamaceuticals, Inc.
    Inventors: Randy W. Scott, Fred Golini, Michael McGrogan
  • Recombinant molecule encoding human protease nexin
    Patent number: 5278049
    Abstract: DNA segments encoding two slightly different protease nexin I forms (PN-I.alpha. and PN-I.beta.) are cloned and expressed to provide practical quantities of PN-I for diagnostic and therapeutic use. PN-I is a serine protease inhibitor useful in controlling conditions mediated by proteolytic activity.
    Type: Grant
    Filed: March 13, 1987
    Date of Patent: January 11, 1994
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Joffre B. Baker, Randy W. Scott
  • Use of protease nexin-I in wound dressings
    Patent number: 5196196
    Abstract: A method of treating wound healing with a composition containing protease nexin-I (PN-I) is disclosed. Compositions comprised of PN-I uniformly dispersed throughout a pharmaceutically acceptable carrier are disclosed as are such compositions further comprising antibiotics. Wound dressings are taught which are comprised of a support base having an absorbent area thereon which has PN-I absorbed thereon and which absorbent area is surrounded by a pressure sensitive adhesive strip for adhering the dressing to a surface surrounding the wound to be treated.
    Type: Grant
    Filed: January 16, 1992
    Date of Patent: March 23, 1993
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Randy W. Scott, Richard A. Berg
  • Protease nexin-I variants which inhibit elastase
    Patent number: 5187089
    Abstract: One or more amino acid residues within the reactive site region of protease nexin-I are altered in order to create analogs or variants or protease nexin-I. These analogs have substantially different protease specificities as well as different effects on regulating the activity of proteolytic enzymes which enzymes have substantial effects on a number of different physiological functions. Formulations containing the protease nexin-I variants and methods for administering these formulations to obtain desirable therapeutic results are disclosed.
    Type: Grant
    Filed: June 21, 1990
    Date of Patent: February 16, 1993
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Randy W. Scott, Fred Golini, Michael McGrogan
  • Use of protease nexin-I to mediate wound healing
    Patent number: 5112608
    Abstract: A method of treating wound healing with a composition containing protease nexin-I (PN-I) is disclosed. Compositions comprised of PN-I uniformly dispersed throughout a pharmaceutically acceptable carrier are disclosed as are such compositions further comprising antibiotics. Occlusive wound dressings are taught which are comprised of a support surface having an absorbent area thereon which has PN-I absorbed thereon and which absorbent area is surrounded by a pressure sensitive adhesive strip for adhering the dressing to a surface surrounding the wound to be treated.
    Type: Grant
    Filed: April 5, 1990
    Date of Patent: May 12, 1992
    Assignee: Incyte Pharmaceuticals
    Inventors: Randy W. Scott, Richard A. Berg
  • Purified protease nexin
    Patent number: 5087368
    Abstract: The gene encoding protease nexin I (PN-I) is cloned and expressed to provide practical quantities of PN-I for diagnostic and therapeutic use. PN-I is a serine protease inhibitor useful in controlling conditions mediated by proteolytic activity.
    Type: Grant
    Filed: September 5, 1990
    Date of Patent: February 11, 1992
    Assignees: Incyte Pharmaceuticals, University of Kansas
    Inventors: Randy W. Scott, Joffre B. Baker
  • Purified protease nexin
    Patent number: 5006252
    Abstract: The gene encoding protease nexin I (PN-I) is cloned and expressed to provide practical quantities of PN-1 for diagnostic and therapeutic use. PN-I is a serine protease inhibitor useful in controlling conditions mediated by proteolytic activity.
    Type: Grant
    Filed: July 10, 1989
    Date of Patent: April 9, 1991
    Assignees: Invitron, University of Kansas
    Inventors: Randy W. Scott, Joffre B. Baker